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To the Editor,
An 11-month-old female patient was admitted to the 
emergency department with right occipital fracture and 
epidural hematoma. The father had severe hemophilia A and the 
parents were cousins. Laboratory tests revealed normal complete 
blood count and prolonged activated partial thromboplastin 
time. Mixing test results were normalized after mixing with 
normal plasma. After plasma samples were collected for further 
diagnostic tests, fresh frozen plasma and dexamethasone were 
administered. The factor VIII level was 0.1%, 35%, and 0.5% 
for the patient, mother, and father, respectively. The patient’s 
von Willebrand factor (VWF) level was 128 IU/mL, VWF:Ricof 
was 110 IU/mL, collagen ADP was 110 (reference: 71-118) s, 
and collagen epinephrine was 98 (reference: 85-165) s. Intron 
22 inversion was investigated with the IS-PCR method and 
was found to be normal. Whole-genome analysis including all 
exonic regions of the F8 gene (NM_000132.3) was conducted 
and the homozygous c.608T>C (L203P) mutation was found. 
This mutation was not previously reported. As this variant was 
not reported in any exome databases (ExAC, EVS) and as it was 
shown to be the cause of the disease in at least three in silico 
protein modeling programs, the mutation was considered as 
a novel mutation causing hemophilia A (“probably damaging” 
with 0.987 PolyPhen2 score, “disease causing” with 0.999 
MutationTaster score, and “damaging” with 0 SIFT score). The 
mutation was also confirmed by Sanger sequencing (Figure 1). 
Plasma-derived FVIII at 2x500 IU/day was administered for 14 
days followed by 300 IU/week prophylaxis. Inhibitor screening 
at the 5th and 10th exposure days was negative. 
Hemophilia A is rarely seen in female patients due to skewed 
inactivation of the X chromosome leading to inactivation of the 
wild-type X chromosome, anomalies like Turner syndrome, or 
translocations, as well as homozygous/compound heterozygous 
mutations for hemophilia A [1,2,3,4,5]. The karyotype analysis 
of our patient revealed 46,XX. The patient and the father were 
hemizygous and mother was heterozygous for the c.608T>C 
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(L203P) mutation (Figure 2). The clinical situation of our patient 
as she was admitted with epidural hematoma requiring surgical 
intervention and the fact that the family did not apply for 
prenatal diagnosis before birth point out the importance of 
prenatal diagnosis in regions where consanguineous marriage 
is common. 
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Figure 1. Sanger sequencing confirmation: (a) the mother (b), the father, and (c) the patient show heterozygous, hemizygous, and 
homozygous c.608T>C (L203P) mutation in the F8 gene. 
Figure 2. Family tree. The patient was homozygous, the father 
hemizygous, and mother heterozygous for the c.608T>C (L203P) 
mutation.
